<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
EYPT
EyePoint
$
()


  • EyePoint reports inducement grants under Nasdaq listing rule

    4/16/2024 - 07:02am
  • EyePoint should be bought on recent weakness, says Mizuho

    4/3/2024 - 06:46am
  • EyePoint expands scientific advisory board with three appointments

    4/2/2024 - 07:03am
  • EyePoint reports inducement grants under Nasdaq listing rule

    3/18/2024 - 07:01am
  • EyePoint expects cash to fund operations through Phase 3 trial data in 2026

    3/7/2024 - 07:05am
  • EyePoint reports Q4 EPS (33c), consensus (49c)

    3/7/2024 - 07:03am
  • EyePoint share weakness a buying opportunity, says Cantor Fitzgerald

    3/5/2024 - 07:23am
  • EyePoint appoints Ribeiro as Chief Medical Officer

    3/4/2024 - 07:10am
  • EyePoint reports inducement grants under Nasdaq listing rule

    2/16/2024 - 07:06am
  • EyePoint price target raised by $9 at Mizuho, here's why

    2/15/2024 - 06:46am
  • EyePoint announced results from new subgroup analyses from Phase 2 DAVIO 2 trial

    2/4/2024 - 07:35am
  • Largest borrow rate increases among liquid names

    1/31/2024 - 08:45am
  • AMD downgraded, American Airlines upgraded: Wall Street's top analyst calls

    1/22/2024 - 09:59am
  • EyePoint initiated with bullish view at JPMorgan, here's why

    1/22/2024 - 05:25am
  • EyePoint director sells $37.2M in common stock

    1/16/2024 - 18:10pm
dynamic_feed Breaking News